The incidence of pancreatic islet cell antibody (ICAb) was assessed in the cord blood and sera of infants of diabetic mothers (IDM). ICAb activity was detected in the cord blood of 10 of 36 (27.8%) consecutive IDM studied and in 0 of 111 (0%) cord bloods of normal control infants. In aU instances, ICAb activity in the cord sera was of the immunoglobulin (I&) class and was associated with ICAb in maternal sera at the time of delivery. No correlation was obsened between the incidence of ICAb in IDM and alterations in fetal growth parameters, congenital malformation rates, cord blood insulin levels, or the incidence of neonatal complications. The evidence would support transplacental passage of ICAb from diabetic mothers to their offspring, but would not support a primary pathogenetic role for ICAb in the clinical or metabolic alterations observed in these infants.
Summary
The incidence of pancreatic islet cell antibody (ICAb) was assessed in the cord blood and sera of infants of diabetic mothers (IDM). ICAb activity was detected in the cord blood of 10 of 36 (27.8%) consecutive IDM studied and in 0 of 111 (0%) cord bloods of normal control infants. In aU instances, ICAb activity in the cord sera was of the immunoglobulin (I&) class and was associated with ICAb in maternal sera at the time of delivery. No correlation was obsened between the incidence of ICAb in IDM and alterations in fetal growth parameters, congenital malformation rates, cord blood insulin levels, or the incidence of neonatal complications. The evidence would support transplacental passage of ICAb from diabetic mothers to their offspring, but would not support a primary pathogenetic role for ICAb in the clinical or metabolic alterations observed in these infants.
Speculation
The detection of ICAb in the cord blood of IDM at birth would suggest a possible role for transplacentally-acquired ICAb in the pathogenesis of the clinical, metabolic, and morphologic abnormalities observed in these infants.
A characteristic spectrum of clinical, metabolic, and morphologic abnormalities have been reported in infants born to diabetic mothers (2, 3, 5, 11) . While various hypotheses have been advanced to explain the pathogenesis of these abnormalities, considerable controversy remains (I I). The demonstration of antibody directed against pancreatic islet cells in the circulation of diabetic populations (1, 6, 7) and the recent case report of ICAb in the cord blood of an IDM (4) have suggested a possible role for transplacentally-acquired ICAb in the pathogenesis of some of the clinical and morphologic abnormalities observed in these infants. The present study was undertaken to assess the incidence of ICAb in cord blood and sera of IDM and to determine if the presence of ICAb is associated with any specific alterations in clinical or metabolic function.
MATERIALS AND METHODS

SUBJECTS
Of 36 consecutive diabetic pregnancies studied, 9 were classified according to White (12) as class A, 10 as class B, I I as class C, and 6 as class D. The age of the diabetic mothers at the time of delivery ranged from 18-35 yr (mean 27.0). The gestational age of the infants ranged from 3 3 4 0 wk (mean 37.3) and the birth weights ranged from 2480-5280 g (mean 3505). Serum samples were obtained from the mother by venipuncture within 24 hr of delivery. Cord blood was obtained from the IDM and followup serum samples were obtained 7 days and 6 months postpartum. Control cord blood samples were obtained from I I I consecutive normal infants. All serum specimens were stored at 20" C. for no longer than 3 months before use.
PROCEDURES
Antibody activity directed against pancreatic islet cells was detected using the indirect immunofluorescent technique (7). Fresh human pancreas obtained from cadaveric renal transplant donors of blood group 0 was employed as the tissue substrate and 5 pm cryostat sections were air dried and futed in acetone at room temperature for 10 min. Undiluted human sera were applied for 30 min, followed by fluorescein-conjugated goat antihuman IgG, IgA, or IgM (Kent Laboratory). Sera positive for ICAb demonstrated a characteristic pattern of cytoplasmic immunofluorescence in all pancreatic islet cells. Titers were measured in serial doubling dilutions of serum beginning at a 1:2 dilution. Preliminary studies ruled out the presence of islet immunofluorescence related to antiinsulin activity by absorbing the sera overnight at 4OC with porcine insulin (Schwarz/Mann) 400 pg/ml and repeating the immunofluorescent studies. Insulin levels in cord sera were determined using a double antibody radioimmunoassay technique (Amersham). All statistical calculations were performed using a step-wise discriminant analysis to separate between the ICAb positive and ICAb negative populations jointly on the basis of the following variables: maternal age at the time of delivery; duration of maternal insulin therapy; duration of maternal diabetes, number of maternal pregnancies, and cord blood insulin levels.
RESULTS
The overall incidence of ICAb activity in the cord blood of 36 consecutive IDM studied was 27.8%. No ICAb activity was observed in 11 1 normal control infants studied over the same time period. In all instances, ICAb activity was of the IgG class and was associated with positive ICAb determinations in maternal sera at the time of delivery. Titers of ICAb activity in positive maternal sera ranged from 1: 1-1: 16 and were consistently within a single doubling dilution of the corresponding cord sera. In two diabetic mothers in which serial ICAb determinations were made throughout the course of the pregnancy, positive ICAb levels were detected from the 12th wk of gestation through full term. ICAb levels remained positive in 7 of 7 IDM tested at 7 days postpartum and were consistently negative by 5-6 months.
Step-wise discriminant analysis of the data indicated no correlation (P > 0.05) between the presence or absence of ICAb and any single variable or linear combination of variables including maternal age at time of delivery, the number of maternal pregnancies (Fig. I) , the duration of maternal diabetes (Fig. 2) , the duration of maternal insulin therapy (Fig. 3) , or cord blood insulin levels (Fig. 4) . No apparent association was noted between the incidence of ICAb in cord blood and congenital malformations (congenital heart disease, renal vein thrombosis etc.); neonatal complications (hypoglycemia, hypocalcemia, hyperbilirubinemia, respiratory distress syndrome); fetal gestation age; fetal growth parameters (Fig. 5) ; or maternal class of diabetes (Fig. 6) although the number in the study group are small. 
DISCUSSION
The present study confirms the presence of ICAb activity in a significant proportion of IDM at birth and for a limited time thereafter. The ICAb would appear to be transplacentally acquired from the maternal circulation based on the observation of ICAb activity only in those infants whose mothers had ICAb detected at the time of delivery; on the restriction of ICAb activity to the IgG class; and on the limited duration of antibody persistence in the postnatal period.
Transplacental passage of maternal autoantibody into the fetal circulation has been reported previously in a wide variety of disease states (4, 8, 9) . The effect on fetal development and neonatal clinical course has been variable. The transfer of platelet antibodies in idiopathic thrombocytopenic purpura, antibodies to conducting tissue in systemic lupus erythematosus, thyroid-stirnulating immunoglobulins in thyrotoxicosis, and antibodies directed against acetylcholine receptor protein in myasthenia gravis (8-10) have been associated with a transient disorder in the infant similar to that of the mother. However, the transplacental passage and development, the incidence of congenital malformations, wrd blood insulin levels, or the neonatal clinical course. However, a possible role still remains for ICAb in the production of morphologic alterations in pancreatic islets observed in a proportion of infants of diabetic mothers. In particular, the reports of periinsular inflammatory cell infiltrates and islet fibrosis in IDM ( 5 , I I) would be consistent with this hypothesis.
